Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$194.00
1.700.88%
Pre-Market: 4:14 AM EDT
Comments
Loading...
Krystal Biotech Analyst Ratings and Price Targets | NASDAQ:KRYS | Benzinga
Krystal Biotech Inc has a consensus price target of $191.08 based on the ratings of 13 analysts. The high is $245 issued by Jefferies on March 5, 2025. The low is $140 issued by B of A Securities on May 25, 2023. The 3 most-recent analyst ratings were released by Jefferies, HC Wainwright & Co., and Citigroup on March 5, 2025, February 28, 2025, and February 20, 2025, respectively. With an average price target of $227 between Jefferies, HC Wainwright & Co., and Citigroup, there's an implied 17.01% upside for Krystal Biotech Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Jefferies
HC Wainwright & Co.
Citigroup
Cantor Fitzgerald
Chardan Capital
1calculated from analyst ratings
Analyst Ratings for Krystal Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/05/2025 | Buy Now | 26.29% | Jefferies | Roger Song33% | → $245 | Initiates | → Buy | Get Alert |
| 02/28/2025 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2025 | Buy Now | 10.82% | Citigroup | Yigal Nochomovitz55% | $206 → $215 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 10.82% | Cantor Fitzgerald | Josh Schimmer55% | → $215 | Reiterates | Overweight → Overweight | Get Alert |
| 02/20/2025 | Buy Now | 12.37% | Chardan Capital | Geulah Livshits45% | $212 → $218 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 9.28% | Chardan Capital | Geulah Livshits45% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/18/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 9.28% | Chardan Capital | Geulah Livshits45% | $212 → $212 | Maintains | Buy | Get Alert |
| 12/10/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 6.19% | Citigroup | Yigal Nochomovitz55% | $204 → $206 | Maintains | Neutral | Get Alert |
| 11/05/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2024 | Buy Now | 13.4% | Stifel | Dae Gon Ha48% | $204 → $220 | Maintains | Buy | Get Alert |
| 08/29/2024 | Buy Now | — | Cantor Fitzgerald | Josh Schimmer55% | — | Reiterates | → Overweight | Get Alert |
| 08/29/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $221 → $221 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2024 | Buy Now | 13.92% | HC Wainwright & Co. | Joseph Pantginis47% | $200 → $221 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 6.19% | Evercore ISI Group | Gavin Clark-Gartner41% | $201 → $206 | Maintains | Outperform | Get Alert |
| 08/06/2024 | Buy Now | 5.15% | Citigroup | Yigal Nochomovitz55% | $195 → $204 | Downgrade | Buy → Neutral | Get Alert |
| 08/05/2024 | Buy Now | 7.22% | Chardan Capital | Geulah Livshits45% | $153 → $208 | Maintains | Buy | Get Alert |
| 08/05/2024 | Buy Now | 3.09% | HC Wainwright & Co. | Joseph Pantginis47% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 3.09% | HC Wainwright & Co. | Joseph Pantginis47% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 3.09% | HC Wainwright & Co. | Joseph Pantginis47% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/22/2024 | Buy Now | 3.09% | HC Wainwright & Co. | Joseph Pantginis47% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/16/2024 | Buy Now | 5.15% | Stifel | Dae Gon Ha48% | $178 → $204 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2024 | Buy Now | 0.52% | Citigroup | Yigal Nochomovitz55% | $160 → $195 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | -9.79% | Guggenheim | Debjit Chattopadhyay55% | $130 → $175 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | -7.22% | Cantor Fitzgerald | Josh Schimmer55% | $160 → $180 | Maintains | Overweight | Get Alert |
| 11/20/2023 | Buy Now | -17.53% | Goldman Sachs | Andrea Tan41% | → $160 | Initiates | → Buy | Get Alert |
| 11/07/2023 | Buy Now | -17.53% | Cantor Fitzgerald | Josh Schimmer55% | → $160 | Reiterates | Overweight → Overweight | Get Alert |
| 10/24/2023 | Buy Now | -17.53% | Cantor Fitzgerald | Josh Schimmer55% | → $160 | Initiates | → Overweight | Get Alert |
| 10/12/2023 | Buy Now | -17.53% | Citigroup | Carly Kenselaar72% | → $160 | Initiates | → Buy | Get Alert |
| 09/07/2023 | Buy Now | -20.62% | Berenberg | Caroline Palomeque59% | → $154 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | -21.13% | Chardan Capital | Geulah Livshits45% | $148 → $153 | Maintains | Buy | Get Alert |
| 08/07/2023 | Buy Now | -28.35% | HC Wainwright & Co. | Joseph Pantginis47% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/27/2023 | Buy Now | -28.35% | HC Wainwright & Co. | Joseph Pantginis47% | → $139 | Reiterates | Buy → Buy | Get Alert |
| 07/03/2023 | Buy Now | -28.35% | HC Wainwright & Co. | Joseph Pantginis47% | → $139 | Reiterates | → Buy | Get Alert |
| 05/25/2023 | Buy Now | -27.84% | B of A Securities | Alec Stranahan33% | $118 → $140 | Maintains | Buy | Get Alert |
| 05/24/2023 | Buy Now | -25.26% | Stifel | Dae Gon Ha48% | $102 → $145 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -32.99% | Guggenheim | Debjit Chattopadhyay55% | $101 → $130 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -20.1% | Goldman Sachs | Madhu Kumar72% | $135 → $155 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -23.71% | Chardan Capital | Geulah Livshits45% | $133 → $148 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -28.35% | HC Wainwright & Co. | Joseph Pantginis47% | $119 → $139 | Maintains | Buy | Get Alert |
| 05/22/2023 | Buy Now | -39.18% | B of A Securities | Alec Stranahan33% | $105 → $118 | Maintains | Buy | Get Alert |
| 05/07/2023 | Buy Now | -30.41% | Goldman Sachs | Madhu Kumar72% | → $135 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | -47.42% | Stifel | Dae Gon Ha48% | → $102 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -47.94% | Guggenheim | Debjit Chattopadhyay55% | → $101 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -38.66% | HC Wainwright & Co. | Joseph Pantginis47% | → $119 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -36.08% | Goldman Sachs | Madhu Kumar72% | $79 → $124 | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2023 | Buy Now | -31.44% | Chardan Capital | Geulah Livshits45% | → $133 | Reiterates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | -31.44% | Chardan Capital | Geulah Livshits45% | $130 → $133 | Maintains | Buy | Get Alert |
| 11/07/2022 | Buy Now | -59.28% | Goldman Sachs | Madhu Kumar72% | $74 → $79 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | -38.66% | HC Wainwright & Co. | Joseph Pantginis47% | $107 → $119 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -61.86% | Goldman Sachs | Madhu Kumar72% | → $74 | Downgrade | Buy → Neutral | Get Alert |
| 08/09/2022 | Buy Now | -32.99% | Chardan Capital | Geulah Livshits45% | $137 → $130 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | -61.86% | Goldman Sachs | Madhu Kumar72% | $78 → $74 | Maintains | Buy | Get Alert |
| 05/24/2022 | Buy Now | -59.79% | Goldman Sachs | Madhu Kumar72% | $91 → $78 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Krystal Biotech (KRYS) stock?
The latest price target for Krystal Biotech (NASDAQ:KRYS) was reported by Jefferies on March 5, 2025. The analyst firm set a price target for $245.00 expecting KRYS to rise to within 12 months (a possible 26.29% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Krystal Biotech (KRYS)?
The latest analyst rating for Krystal Biotech (NASDAQ:KRYS) was provided by Jefferies, and Krystal Biotech initiated their buy rating.
When was the last upgrade for Krystal Biotech (KRYS)?
The last upgrade for Krystal Biotech Inc happened on February 28, 2023 when Goldman Sachs raised their price target to $124. Goldman Sachs previously had a neutral for Krystal Biotech Inc.
When was the last downgrade for Krystal Biotech (KRYS)?
The last downgrade for Krystal Biotech Inc happened on August 6, 2024 when Citigroup changed their price target from $195 to $204 for Krystal Biotech Inc.
When is the next analyst rating going to be posted or updated for Krystal Biotech (KRYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Krystal Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Krystal Biotech was filed on March 5, 2025 so you should expect the next rating to be made available sometime around March 5, 2026.
Is the Analyst Rating Krystal Biotech (KRYS) correct?
While ratings are subjective and will change, the latest Krystal Biotech (KRYS) rating was a initiated with a price target of $0.00 to $245.00. The current price Krystal Biotech (KRYS) is trading at is $194.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.